ClinConnect ClinConnect Logo
Search / Trial NCT06987253

Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Oral Cavity Surgery

Launched by ENIKAM D.O.O. · May 15, 2025

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Oral Cavity Wound Hydrogen Peroxide Mouthwash

ClinConnect Summary

This clinical trial is studying a mouthwash called OROXID® to see if it can help people heal better after having their wisdom teeth removed. The researchers believe that OROXID® might reduce pain and complications after surgery and promote faster healing by cleaning the mouth and reducing bacteria. This mouthwash works by releasing oxygen bubbles that help remove debris and keeps the area moist, which is important for healing.

To participate in the trial, you need to be at least 18 years old and in good health. You should be scheduled for oral surgery, like wisdom tooth extraction, and be willing to follow post-surgery care instructions. However, if you've had certain dental treatments recently, have specific oral health issues, or are pregnant or breastfeeding, you may not be eligible to join. Participants will use OROXID® as directed and monitor their recovery, helping researchers understand its effectiveness and safety.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Systemically healthy individuals aged 18 years or older.
  • 2. Indicated for surgical removal of an erupted or unerupted tooth and/or apicoectomy.
  • 3. Ability and willingness to comply with post-operative oral hygiene instructions.
  • 4. Signed informed consent form prior to participation in the study.
  • Exclusion Criteria:
  • 1. Receipt of periodontal treatment within the past 3 months.
  • 2. Use of mouthwashes or oral gels in the past month.
  • 3. Presence of active gingivitis around the tooth scheduled for extraction.
  • 4. Known allergy to any ingredients of the investigational products.
  • 5. Presence of inflammatory conditions in the oral cavity, such as lichen planus, bullous lesions, or active gingivitis.
  • 6. Immunocompromised individuals.
  • 7. Known allergy to penicillin or diclofenac.
  • 8. Pregnant or breastfeeding women.
  • 9. Smokers who consume more than 15 cigarettes per day.

About Enikam D.O.O.

Enikam d.o.o. is a forward-thinking clinical trial sponsor dedicated to advancing medical research and innovation. With a focus on developing novel therapeutic solutions, Enikam partners with healthcare professionals and research institutions to conduct rigorous clinical trials that adhere to the highest ethical and regulatory standards. The company is committed to enhancing patient outcomes through evidence-based practices and cutting-edge methodologies, fostering collaboration across diverse therapeutic areas. Enikam’s expertise and dedication to scientific excellence position it as a pivotal player in the global clinical research landscape.

Locations

Muljava, Ivančna Gorica, Slovenia

Muljava, , Slovenia

Patients applied

0 patients applied

Trial Officials

Tadej Dovšak, PhD

Principal Investigator

Krizaj d.o.o.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported